SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 124 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $188,237 | -31.2% | 12,964 | -0.8% | 0.00% | 0.0% |
Q2 2023 | $273,597 | +34.5% | 13,072 | +35.7% | 0.00% | 0.0% |
Q1 2023 | $203,449 | -17.9% | 9,633 | -1.0% | 0.00% | 0.0% |
Q4 2022 | $247,679 | +22.0% | 9,732 | +15.0% | 0.00% | 0.0% |
Q3 2022 | $203,000 | +24.5% | 8,460 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $163,000 | +77.2% | 8,460 | +60.4% | 0.00% | – |
Q1 2022 | $92,000 | -33.3% | 5,273 | -16.4% | 0.00% | -100.0% |
Q4 2021 | $138,000 | +11.3% | 6,306 | -2.7% | 0.00% | 0.0% |
Q3 2021 | $124,000 | +11.7% | 6,482 | +0.1% | 0.00% | 0.0% |
Q2 2021 | $111,000 | +4.7% | 6,473 | +36.4% | 0.00% | 0.0% |
Q1 2021 | $106,000 | – | 4,744 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |